生长抑素治疗肥胖的分子机制研究进展

doi:10.20047/j.issn1673-7210.2023.15.10

Abstract
Figure/Table
References (31)
Related Citation (15)

Download: PDF (511 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract The prevalence of obesity is increasing year by year, and obesity is a potential risk factor for many chronic diseases. However, obesity treatment faces problems such as few drug options and many side effects. Somatostatin (SST) plays an important role in food intake and appetite regulation. More and more evidence suggests that SST has potential value of clinical application in the management of obesity by affecting satiety and feeding behavior. SST can effectively regulate the occurrence and development of obesity and its related diseases by forming a wide regulatory network with insulin, agouti-related peptide, proopiomelanocortin, leptin, ghrelin, and brain-derived neurotrophic factor. The in-depth study of the role and mechanism of SST in weight loss will open up a new perspective for the development of new drugs for the treatment of obesity. In addition, considering the limitations of natural hormones, SST analogs are good candidates for the treatment of obesity and are expected to be widely developed for clinical application. According to the existing problems, this paper also proposes specific research directions in the future, aiming at providing relevant scientific basis for the treatment of obesity.

Key words： Somatostatin Somatostatin receptors Obesity Satiety

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	SUN Shuoshuo1 WEI Xiao1 ZHANG Shaohong2 LIU Chao1

Cite this article:

SUN Shuoshuo1 WEI Xiao1 ZHANG Shaohong2 LIU Chao1. Research progress on the molecular mechanism of somatostatin in the treatment of obesity[J]. 中国医药导报, 2023, 20(15): 53-56.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.15.10 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I15/53

[1] Kumar U，Singh S. Role of somatostatin in the regulation of central and peripheral factors of satiety and obesity [J]. Int J Mol Sci，2020，21（7）：2568.
[2] Chen VP，Gao Y，Geng L，et al. Butyrylcholinesterase gene transfer in obese mice prevents postdieting body weight rebound by suppressing ghrelin signaling [J]. Proc Natl Acad Sci USA，2017，114（41）：10960-10965.
[3] Blüher M. Obesity：global epidemiology and pathogenesis [J]. Nat Rev Endocrinol，2019，15（5）：288-298.
[4] Liguz-Lecznar M，Dobrzanski G，Kossut M. Somatostatin and somatostatin-containing interneurons-from plasticity to pathology [J]. Biomolecules，2022，12（2）：312.
[5] Eychenne R，Bouvry C，Bourgeois M，et al. Overview of radiolabeled somatostatin analogs for cancer imaging and therapy [J]. Molecules，2020，25（17）：4012.
[6] Andersen MR，Suppli MP，Bagger JI，et al. MECHANISMS IN ENDOCRINOLOGY：the physiology of neuronostatin [J]. Eur J Endocrinol，2021，185（4）：R93-R101.
[7] Ampofo E，Nalbach L，Menger MD，et al. Regulatory mechanisms of somatostatin expression [J]. Int J Mol Sci，2020，21（11）：4170.
[8] Rogoza O，Megnis K，Kudrjavceva M，et al. Role of somatostatin signalling in neuroendocrine tumours [J]. Int J Mol Sci，2022，23（3）：1447.
[9] Gonzalez-Rodriguez M，Astillero-Lopez V，Villanueva-Anguita P，et al. Somatostatin and astroglial involvement in the human limbic system in Alzheimer’s disease [J]. Int J Mol Sci，2021，22（16）：8434.
[10] Robinson SL，Thiele TE. A role for the neuropeptide somatostatin in the neurobiology of behaviors associated with substances abuse and affective disorders [J]. Neuropharmacology，2020，167：107983.
[11] Aslam M，Idrees H，Ferdinandy P，et al. Somatostatin primes endothelial cells for agonist-induced hyperpermeability and angiogenesis in vitro [J]. Int J Mol Sci，2022，23（6）：3098.
[12] Rorsman P，Huising MO. The somatostatin-secreting pancreatic δ-cell in health and disease [J]. Nat Rev Endocrinol，2018，14（7）：404-414.
[13] Saiz-Sanchez D，Ubeda-Ba?觡on I，Flores-Cuadrado A，et al. Somatostatin，olfaction，and neurodegeneration [J]. Front Neurosci，2020，14：96.
[14] Gomes-Porras M，Cárdenas-Salas J，?譧lvarez-Escolá C. Somatostatin analogs in clinical practice：a review [J]. Int J Mol Sci，2020，21（5）：1682.
[15] Fuentes-Fayos AC，G-García ME，Pérez-Gómez JM，et al. Somatostatin receptor splicing variant sst5TMD4 overexpression in glioblastoma is associated with poor survival，increased aggressiveness features，and somatostatin analogs resistance [J]. Int J Mol Sci，2022，23（3）：1143.
[16] Hu Y，Ye Z，Wang F，et al. Role of somatostatin receptor in pancreatic neuroendocrine tumor development，diagnosis， and therapy [J]. Front Endocrinol（Lausanne），2021，12：679000.
[17] Pittaluga A，Roggeri A，Vallarino G，et al. Somatostatin，a pres- ynaptic modulator of glutamatergic signal in the central nervous system [J]. Int J Mol Sci，2021，22（11）：5864.
[18] Shamsi BH，Chatoo M，Xu XK，et al. Versatile functions of somatostatin and somatostatin receptors in the gastrointestinal system [J]. Front Endocrinol（Lausanne），2021，12：652363.
[19] Heo Y，Yoon E，Jeon YE，et al. Cryo-EM structure of the human somatostatin receptor 2 complex with its agonist somatostatin delineates the ligand-binding specificity [J]. Elife，2022，11：e76823.
[20] Costanzi E，Simioni C，Conti I，et al. Two neuroendocrine G protein-coupled receptor molecules，somatostatin and melatonin：physiology of signal transduction and therapeutic perspectives [J]. J Cell Physiol，2021，236（4）：2505-2518.
[21] Srivastava G，Apovian C. Future pharmacotherapy for obesity：new anti-obesity drugs on the horizon [J]. Curr Obes Rep，2018，7（2）：147-161.
[22] Stengel A，Karasawa H，Taché Y. The role of brain somatostatin receptor 2 in the regulation of feeding and drinking behavior [J]. Horm Behav，2015，73：15-22.
[23] Svendsen B，Holst JJ. Paracrine regulation of somatostatin secretion by insulin and glucagon in mouse pancreatic islets [J]. Diabetologia，2021，64（1）：142-151.
[24] Czech MP. Insulin action and resistance in obesity and type 2 diabetes [J]. Nat Med，2017，23（7）：804-814.
[25] van Iersel L，Brokke KE，Adan RAH，et al. Pathophysiology and individualized treatment of hypothalamic obesity following craniopharyngioma and other suprasellar tumors：a systematic review [J]. Endocr Rev，2019，40（1）：193-235.
[26] Campbell JN，Macosko EZ，Fenselau H，et al. A molecular census of arcuate hypothalamus and median eminence cell types [J]. Nat Neurosci，2017，20（3）：484-496.
[27] L?觟hr H，Hess S，Pereira MMA，et al. Diet-induced growth is regulated via acquired leptin resistance and engages a pomc-somatostatin-growth hormone circuit [J]. Cell Rep，2018，23（6）：1728-1741.
[28] D’souza AM，Neumann UH，Glavas MM，et al. The glucoregulatory actions of leptin [J]. Mol Metab，2017，6（9）：1052-1065.
[29] Müller TD，Nogueiras R，Andermann ML，et al. Ghrelin [J]. Mol Metab，2015，4（6）：437-460.
[30] Stengel A，Taché Y. Activation of somatostatin 2 receptors in the brain and the periphery induces opposite changes in circulating ghrelin levels：functional implications [J]. Front Endocrinol（Lausanne），2012，3：178.
[31] Larocca AV，Toniolo G，Tortorella S，et al. The entrapment of somatostatin in a lipid formulation：retarded release and free radical reactivity [J]. Molecules，2019，24（17）：3085.